Cancer clinical trials in the region Pays de la Loire
436 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Rectal cancer
#NCT06762405
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Radiotherapy
10 recruiting sites
CHU Dijon
Phase 3
Prostate cancer
#NCT06625970
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required PSMA PET Scan statuses
PSMA PET Negative
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery
Radiotherapy
Internal Vectorised Radiotherapy (IVR)
11 recruiting sites
UNICANCER
Phase 2 / Phase 3
Multiple myeloma
#NCT07095452
#2025-520897-21-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IMWG cytogenetic prognoses
High risk
15 recruiting sites
Abbvie
Phase 2 / Phase 3
Endometrial cancer
#NCT03651206
#2024-516782-36-00
Required histologic sub types
Carcinosarcoma
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Immunotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
Targeted therapy
16 recruiting sites
ARCAGY/ GINECO GROUP
Phase 2 / Phase 3
Acute leukemia
#NCT07581002
#2025-523724-47-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
Excluded previous treatments
Chemotherapy
Targeted therapy
Car-T
4 recruiting sites
Abbvie
Phase 2 / Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT07129993
#2024-516906-47-00
Required histologic types
Invasive bladder cancer
Upper excretory tract cancer
Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
Daiichi Sankyo
Phase 2 / Phase 3
Skin cancer
#NCT06697301
#2024-512659-19-00
Required histologic types
Melanoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Radiotherapy
10 recruiting sites
Eikon Therapeutics
Phase 2 / Phase 3
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Stomach and esophageal cancer
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT06943755
#2025-521043-20-00
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Exélixis
Phase 2 / Phase 3
Stomach and esophageal cancer
#NCT07221149
#2025-523263-37-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Negative (< 1)
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
5 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3
Lung cancer
#NCT07100080
#2025-521908-22-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
1 recruiting site
Bristol-Myers Squibb